Abstract
Several clinical and cell biological features, such as sex, age, leukemic cell burden, morphologic FAB type, and immunophenotype, have prognostic value in childhood acute lymphoblastic leukemia (ALL). The explanation for their prognostic significance is unclear, but might be related to cellular drug resistance. We prospectively studied the relation between the above mentioned features with resistance to 13 drugs in 144 childhood ALL samples obtained at initial diagnosis. The MTT assay was used for drug resistance testing. The interindividual differences in drug resistance were very large and exceeded those between the several subgroups. There was generally no significant relation between sex, leukemic cell burden, and FAB type with drug resistance. However, subgroups with a worse prognosis as defined by age (< 18 months and > 120 months at diagnosis) or immunophenotype (pro-B ALL and T-ALL) did show relatively resistant drug resistance profiles as compared to the subgroups with a better prognosis (age 18-120 months, common and pre-B ALL). Within the group of common and pre-B ALL and compared to the intermediate age-group, samples of the younger children were significantly more resistant to daunorubicin, mitoxantrone and tenipos...Continue Reading
References
May 1, 1992·British Journal of Haematology·J S LilleymanC C Bailey
Jan 22, 1991·Lancet·G K RiveraD L Williams
Aug 17, 1991·Lancet·R PietersA J Veerman
Jan 21, 1992·International Journal of Cancer. Journal International Du Cancer·R LarssonP Nygren
Sep 1, 1991·British Journal of Cancer·G J KaspersA J Veerman
Jan 1, 1991·Leukemia Research·H PreislerC Kukla
Aug 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G D Hammond
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K NooterA Hagenbeek
Apr 1, 1990·British Journal of Haematology·A J Veerman, R Pieters
Mar 15, 1990·Cancer·T HongoY Igarashi
Jan 1, 1990·Leukemia Research·D L KirkpatrickT S Goh
Aug 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S C RaimondiG K Rivera
Oct 1, 1989·Pediatric Clinics of North America·W E EvansM Sunderland
Jun 1, 1989·British Journal of Haematology·J P VannierA Bernard
Aug 1, 1989·British Journal of Cancer·J M Sargent, C G Taylor
Feb 1, 1989·British Journal of Haematology·J S Lilleyman, R F Hinchliffe
Feb 1, 1989·British Journal of Cancer·R PietersA J Veerman
Sep 11, 1986·The New England Journal of Medicine·L A ClavellS E Sallan
Jan 1, 1986·Leukemia Research·C H PuiJ Mirro
Aug 1, 1988·Pediatric Clinics of North America·D G Poplack, G Reaman
May 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E KokenbergB Löwenberg
Aug 30, 1988·Cancer Letters·R PietersA J Veerman
Jan 1, 1986·Medical and Pediatric Oncology·D HammondS Siegel
Sep 1, 1986·Journal of Clinical Pathology·J S LilleymanS M Richards
Apr 4, 1981·Lancet·H SatherD Hammond
Apr 1, 1981·British Journal of Haematology·J M BennettC Sultan
Jun 1, 1981·British Journal of Haematology·M F GreavesH Kay
Sep 1, 1994·Molecular Endocrinology·S Reisfeld, L Vardimon
Dec 1, 1994·British Journal of Cancer·G J KaspersK Hählen
Jan 1, 1993·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·E R van WeringJ J van Dongen
Citations
Jan 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Henze
Jan 1, 1997·Critical Reviews in Oncology/hematology·R PietersA J Veerman
May 5, 1999·Critical Reviews in Oncology/hematology·C E GiddingS S de Graaf
Nov 11, 1999·British Journal of Haematology·M L Den BoerA J Veerman
Dec 20, 2002·Current Opinion in Oncology·Yaddanapudi Ravindranath
Sep 29, 2005·Blood·Amy HollemanRob Pieters
Jun 27, 2002·Pediatric Research·Ellis GroningerSiebold de Graaf
Aug 5, 2014·PloS One·Sheila Xinxuan SohS Tiong Ong
Mar 31, 2007·Annals of Hematology·Manchao ZhangDajun Yang
Jun 4, 2008·Annals of Hematology·Gunnar CarioMartin Schrappe
May 10, 2002·Leukemia & Lymphoma·Jan Styczynski, Mariusz Wysocki
Sep 24, 1999·Leukemia & Lymphoma·Y Messinger, F M Uckun
Nov 3, 2005·Leukemia & Lymphoma·Monika M TreboHelmut Gadner
Feb 12, 2014·Expert Opinion on Drug Metabolism & Toxicology·Rabih Said, Apostolia Maria Tsimberidou
Aug 13, 2009·Pediatric Blood & Cancer·Maria A A CortezLuiz G Tone
Jul 16, 2005·Leukemia & Lymphoma·Süreyya SavaşanYaddanapudi Ravindranath
Aug 28, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Dominique J P M StumpelRonald W Stam
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L Den BoerG E Janka-Schaub
Jun 1, 2002·Leukemia·W A KampsA van der Does-van den Berg
Apr 12, 2013·Experimental Hematology & Oncology·Fung Kwong-Lam, Chan Godfrey Chi-Fung
Sep 1, 1996·Leukemia & Lymphoma·C PeschelC Huber
May 16, 2002·Blood·Christian WuchterLeonid Karawajew
Dec 6, 2006·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J F MataL G Tone